Company will also create 25 jobs this year Galway-based medtech company Bluedrop Medical has raised €10.5 million in a funding round that will help further the development of its remote patient monitoring system for the early detection of diabetic foot ulcers. Read Full Article in the Irish Times
About AR MemberThis author has not yet filled in any details.
So far AR Member has created 12 blog entries.
Cork-based medical technologies company, AventaMed has been acquired by German firm, Karl Storz for an undisclosed amount. Originally spun out of Munster Technological University in 2015, the Cork firm developed a breakthrough single-use medical device, Solo+ TTD that addresses pain points of the current treatment of the surgical tympanostomy, a procedure that drains out the excess fluid built up in the ear. Read Full Article in the Examiner
Irish medtech company ProVerum has raised €30 million to support its clinical programme as it looks to go to market with its ground-breaking ProVee device in both Europe and the US. The series A funding round was co-led by Gilde Healthcare and Lightstone Ventures, with Atlantic Bridge and other existing investors also participating. ProVerum, which was founded by Ríona Ní Ghriallais and Conor Harkin in 2016 as a spinout from Trinity College Dublin, has developed a novel treatment solution for patients with symptomatic benign prostatic hyperplasia (BPH). This is a common condition where the prostate gland is enlarged, causing difficultly with urination and potentially kidney problems too. Read Full Article on the [...]
Sigrid Therapeutics raises funding of $8.4M from US, Irish and Swedish investors for diabetes breakthrough2021-11-16T17:06:38+00:00
STOCKHOLM, Nov. 10, 2021 /PRNewswire/ -- Swedish healthtech startup Sigrid Therapeutics is set to prevent two of the world's biggest health challenges, type 2 diabetes and obesity with its SiPore15® powder. This vision has attracted a number of Sweden's family offices to invest just over $8.4 million in new capital making a total since inception of $17.5 million. "A quarter of the world population is affected with chronic lifestyle diseases which are preventable. That is why we created SiPore15® a patented silica-based powder clinically proven to lower long-term blood sugar and a range of metabolic parameters. Designed to act locally in the gut SiPore15® consists of precisely engineered micron-sized silica [...]
Angle investment into Irish start-ups is now higher than at pre-pandemic levels and thriving, according to figures from a business angels network. It says angels invested £7 million in fledgling businesses on the island of Ireland in the first half of this year, which was up 13 per cent when compared to the same pre-pandemic period in 2019. And the HBAN (Halo Business Angel Network), the all-island organisation responsible for the promotion of business angel investment, says that since its inception some £338 million has been pumped into start-ups through its network. HBAN, which is a joint initiative of Enterprise Ireland, [...]
Irish online advertising software company StitcherAds has been acquired in a $64 million (€55million) deal. The buyer is US adtech company Kargo, which is looking to exceed $100 million in revenues this year. The deal was first reported by the Wall Street Journal on Monday. StitcherAds, which earlier this year announced plans to create 40 jobs, is a marketing platform that helps advertisers publish paid ads that drive sales via Facebook, Instagram, Pinterest and Snapchat, while also providing useful analytics. Its customers include Wayfair, Calvin Klein, and Bed Bath and Beyond. Read Full Article on Irish Times
Funding will accelerate development of wearable monitor to detect osteoarthritis-related pain in companion animals Backed by experienced seed investors including Irrus Investments, Pro-Vet and Stonehaven Incubate Seed financing planned for 2022 to further drive product development and commercialization Investment by Pro-Vet enables for commercialization in China and other Asian countries Delaware, US, 4 October 2021 – AniV8, a leading developer of clinical sensor technology to diagnose and monitor diseases affecting companion animals, today announced the completion of its pre-seed funding round, which closed significantly above its original target. The funds raised will enable AniV8 to conduct larger clinical studies using its unique [...]
With patented polymer Sfere technology, Qualus is helping tanneries around the world reduce water consumption by up to 40% and chemicals by up to 15% LONDON – Qualus, the leading provider of sustainable solutions to the leather industry, has secured £1 million of financing in a round led by Irrus Investments, an Ireland based angel syndicate. Co-investors in the round include CPI Enterprises and angels from Cambridge Capital Group and Harvard Business School Alumni Angels of London. After years of optimising its solution through in-field trials at tanneries, Qualus now has multiple customers transitioning all production to its innovative system and a strong [...]
Mirai Medical Announces First Patient Enrolled in VECTOR Trial using ePORE® therapy for the Treatment of Inoperable Oesophageal and Gastric Cancer2021-11-04T11:39:51+00:00
Mirai Medical Ltd, a manufacturer of a precision cancer therapy platform , today announced the first procedures in the clinical trial to evaluate ePORE® therapy and EndoVE®, a novel breakthrough technology that can treat gastrointestinal cancers endoscopically in an outpatient setting with minimum hospitalisation for the patient. The first procedure in the VECTOR trial (NCT04649372) was performed this week at Nottingham NHS Trust, United Kingdom in a team led by Mr. Simon Parsons. The VECTOR trial aims to establish the safety and efficacy of treating patients with inoperable oesophageal cancer or gastric cancer in an outpatient setting, using an endoscopic system [...]
ATHENS, Ga. and RESEARCH TRIANGLE PARK, N.C., April 14, 2021 (GLOBE NEWSWIRE) -- Aruna Bio, Inc., a leader in the development of neural exosomes for the treatment of neurodegenerative diseases, today announced the closing of a common stock financing totalling $10.8 million. Proceeds from the raise will support the company’s business plan through mid-2022. “This capital will allow us to continue our efforts to deliver important therapeutics to the central nervous system using a novel approach to potentially treat a number of extremely debilitating neurodegenerative diseases,” stated Dr. Mark A. Sirgo, Chief Executive Officer. Read Full Article on Globe Newswire